Back to Treatments

Treatment

Palbociclib (CDK4/6 Inhibitor)

1
Conditions
74
Trials
15K
Participants
45%
Average Safety

Condition Evidence

Breast cancer

74 trials · 15K participants

65% effectiveness · 45% safety
Palbociclib (CDK4/6 Inhibitor) | DFDA